Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Idursulfase beta

            Therapeutic Area: Genetic Disease Product Name: Hunterase

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: 3W Fund Management

            Deal Size: $43.0 million Upfront Cash: Undisclosed

            Deal Type: Series E Financing December 01, 2020


            The proceeds will be used to expand the CANbridge rare disease pipeline through internal development and external partnerships, accelerate the clinical development of pre-clinical stage assets, prepare the commercial launch of Hunterase® and supplement working capital.